Combination therapy for advanced solid tumors linked to HPV
Part of Cancer clinical trials.
This study tests a new combination treatment for advanced solid tumors caused by HPV types 16 or 18. It aims to see if the treatment is safe and effective for people who have tried standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must test positive for HPV type 16 and/or 18.
- You must have an advanced solid tumor that cannot be removed by surgery or has spread to other parts of the body.
- You should be able to care for yourself (ECOG score 0-1) and have a life expectancy of at least 3 months.
- Your major organs (like liver, kidneys, blood cells) must be working well enough, as shown by blood tests.
- You must agree to use reliable birth control during the study and for 6 months after the last dose.
- You must have at least one tumor that can be measured on scans (RECIST 1.1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BM230) combined with a PD-1 inhibitor (a type of immunotherapy) for advanced cancers that have HER2. It aims to see if the combination is safe and effective in treating tumors that have stopped responding to standard treatments.
This study tests a new drug (SYS6006) combined with an existing immunotherapy (called Enlonstobart) to see if it works better than the immunotherapy alone for people with advanced solid tumors. It may help shrink or slow the growth of your cancer.
This trial tests two experimental drugs given together to treat advanced solid tumors that have not responded to previous treatments. The goal is to see if the combination helps shrink or control the cancer, and the study is for people who are otherwise in fairly good health.
This trial is testing a new combination treatment, SYS6010 plus enlonstobart, for people with head and neck squamous cell carcinoma that has come back or spread. It aims to see if this combination works better than enlonstobart alone.
This study tests a new treatment using your own immune cells (called SCG142) that are specially trained to attack cancer cells linked to HPV 16 or 52. It may help people with advanced squamous cell cancers who have not gotten better with standard treatments.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.